Harmful cholesterol levels cut in half with one-time gene editing drug in early trial
Altering a single gene may help people lower dangerously high levels of cholesterol and other fats in the…
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
CRISPR Therapeutics AG -Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a…
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
An updated edition of the June 27, 2025, article. Genomics encompasses the study of a complete set of…